Search Results

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” deal for the pharma.

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR Pharmaceuticals for use in up to five of Alexion’s gene therapies.

Alexion Pharma Canada Corp., AstraZeneca’s Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.

JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo ® Technology for Neurodegenerative Disease in Research Collaboration with Alexion.

Verge Genomics today announced a multi-target collaboration with Alexion, AstraZeneca Rare Disease (“Alexion”) to identify novel drug targets for rare neurodegenerative and neuromuscular diseases.

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida: “JCR”) announces that it has signed a Research Collaboration, Option and License Agreement with Alexion, AstraZeneca Rare Disease (“Alexion”) for the development of novel oligonucleotide therapeutics to support targeted delivery to certain tissues or organs using J-Brain Cargo®, JCR’s proprietary blood-brain barrier (BBB)-penetrating technology.

After nearly seven years, the company’s rare diseases arm Alexion has reached a settlement in an investors’ lawsuit over alleged unethical sales practices for its hemoglobinuria therapy Soliris.